BioPharmSignal logoBioPharmSignal

Biotech News

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics (AVTX)Avalo TherapeuticsEarnings

AVTX (AVTX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is avtx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

SNGXSOLIGENIX2026-08-07 11:30 EST

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

ACRSAclaris Therapeutics2026-08-06 10:59 EST

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

CUECue Biopharma Inc2026-05-14 20:07 EST

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments

View all latest news

Avalo Therapeutics

Clinical Immunology Company Avalo Therapeutics develops therapies for immune-mediated inflammatory diseases. Abdakibart Abdakibart is an antibody targeting IL-1β and is being developed for moderate-to-severe hidradenitis suppurativa. LOTUS Evidence The Phase 2 LOTUS study met its primary endpoint at both evaluated doses, supporting...

Recent company news

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

AVTXAvalo Therapeutics2026-07-07 11:00 EST

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

AVTXAvalo Therapeutics2026-06-26 11:00 EST

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

AVTXAvalo Therapeutics2026-06-23 11:00 EST

Avalo Therapeutics Appoints Ron Philip to Board of Directors

Stock data

Close
18.70 USD
Market cap
733.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States